SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000935836-21-000174
Filing Date
2021-02-16
Accepted
2021-02-16 16:00:38
Documents
1

Document Format Files

Seq Description Document Type Size
1 keros13ga.htm SC 13G/A 59308
  Complete submission text file 0000935836-21-000174.txt   60947
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91484 | Film No.: 21637699
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O OGIER GLOBAL (CAYMAN) LIMITED 89 NEXUS WAY CAMANA BAY E9 KY1-9009
Business Address C/O OGIER GLOBAL (CAYMAN) LIMITED 89 NEXUS WAY CAMANA BAY E9 KY1-9009 (415) 801-4675
Logos Global Master Fund LP (Filed by) CIK: 0001831371 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G/A